Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jul;9(7):2444-53.
doi: 10.3390/ijerph9072444. Epub 2012 Jul 10.

Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor

Sachiko Ezoe  1
Affiliations
Review

Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor

Sachiko Ezoe. Int J Environ Res Public Health. 2012 Jul.

Abstract

Etoposide is an anticancer agent, which is successfully and extensively used in treatments for various types of cancers in children and adults. However, due to the increases in survival and overall cure rate of cancer patients, interest has arisen on the potential risk of this agent for therapy-related secondary leukemia. Topoisomerase II inhibitors, including etoposide and teniposide, frequently cause rearrangements involving the mixed lineage leukemia (MLL) gene on chromosome 11q23, which is associated with secondary leukemia. The prognosis is extremely poor for leukemias associated with rearrangements in the MLL gene, including etoposide-related secondary leukemias. It is of great importance to gain precise knowledge of the clinical aspects of these diseases and the mechanism underlying the leukemogenesis induced by this agent to ensure correct assessments of current and future therapy strategies. Here, I will review current knowledge regarding the clinical aspects of etoposide-related secondary leukemia, some probable mechanisms, and strategies for treating etoposide-induced leukemia.

Keywords: MLL; etoposide; secondary leukemia; treatment.

PubMed Disclaimer

References

    1. Hande K.R. Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer. 1998;34:1514–1521. - PubMed
    1. Ratain M.J., Kaminer L.S., Bitran J.D., Larson R.A., Le Beau M.M., Skosey C., Purl S., Hoffman P.C., Wade J., Vardiman J.W., et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood. 1987;70:1412–1417. - PubMed
    1. Potzsch C., Fetscher S., Mertelsmann R., Lubbert M. Acute myelomonocytic leukemia secondary to synchronous carcinomas of the breast and lung, and to metachronous renal cell carcinoma. J. Cancer Res. Clin. Oncol. 1997;123:678–680. - PubMed
    1. Shearer P., Kapoor G., Beckwith J.B., Takashima J., Breslow N., Green D.M. Secondary acute myelogenous leukemia in patients previously treated for childhood renal tumors: A report from the National Wilms Tumor Study Group. J. Pediatr. Hematol. Oncol. 2001;23:109–111. - PubMed
    1. Domer P.H., Head D.R., Renganathan N., Raimondi S.C., Yang E., Atlas M. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11) Leukemia. 1995;9:1305–1312. - PubMed

MeSH terms

Substances